Lampertico, Pietro, Mauss, Stefan, Persico, Marcello, Barclay, Stephen T, Marx, Steven, Lohmann, Kristina, Bondin, Mark, Zhang, ZhenZhen, Marra, Fiona 
ORCID: 0000-0003-1326-1149, Belperio, Pamela S et al (show 2 more authors)
(2020)
Real-World Clinical Practice Use of 8-Week Glecaprevir/Pibrentasvir in Treatment-Naive Patients with Compensated Cirrhosis.
ADVANCES IN THERAPY, 37 (9).
pp. 4033-4042.
|
Text
Real-World Clinical Practice Use of 8-Week GlecaprevirPibrentasvir in Treatment-Naïve Patients with Compensated Cirrhosis.pdf - Published Version Download (450kB) | Preview |
Abstract
<h4>Introduction</h4>More than 70 million people are estimated to be infected with hepatitis C virus globally. Glecaprevir/pibrentasvir is a widely used treatment and has recently been approved for an 8-week regimen for treatment-naïve patients with compensated cirrhosis in Europe and the USA, who would previously have received glecaprevir/pibrentasvir for 12 weeks. This label update was based on the EXPEDITION-8 study, which included 343 treatment-naïve patients with compensated cirrhosis. However, there is currently a lack of similarly large-scale real-world studies of the 8-week glecaprevir/pibrentasvir regimen in this population.<h4>Methods</h4>This summary of seven separate smaller real-world studies aims to validate the results seen in EXPEDITION-8 and provide an up-to-date real-world reference for clinicians making treatment decisions for patients with compensated cirrhosis (Child-Pugh A) who may benefit from a shorter-duration therapy with glecaprevir/pibrentasvir. The newly emerging real-world effectiveness data on treatment-naïve patients with compensated cirrhosis treated with 8 weeks of glecaprevir/pibrentasvir help to understand where further research is needed to support patients with hepatitis C virus.<h4>Results</h4>Across all seven studies, glecaprevir/pibrentasvir showed high effectiveness with an average sustained virologic response rate of 98.1%, similar to that found in a clinical trial setting (99.7%). Only one patient (0.5%) experienced virologic failure and treatment was well tolerated.<h4>Conclusion</h4>Expanding the number of patients eligible for the shortened treatment duration will potentially increase treatment initiation and completion, particularly in underserved populations, contributing to the elimination of hepatitis C virus.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | Fibrosis, Hepatitis C, Infectious disease, Review, Therapeutics |
| Depositing User: | Symplectic Admin |
| Date Deposited: | 12 Jan 2021 10:45 |
| Last Modified: | 18 Jan 2023 23:05 |
| DOI: | 10.1007/s12325-020-01449-0 |
| Open Access URL: | http://doi.org/10.1007/s12325-020-01449-0 |
| Related URLs: | |
| URI: | https://livrepository.liverpool.ac.uk/id/eprint/3111916 |
Dimensions
Dimensions
